Ranbaxy Laboratories has launched the authorized cevimeline hydrochloride capsules, generic version of its parent Daiichi Sankyo’s Evoxac in the US.
Ranbaxy has launched the drug, used for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands, through its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. The drug is launched in a strength of 30 mg.
Ranbaxy has launched the drug under an agreement with Daiichi Sankyo. However, the details are of the pact are not known. Evoxac, the brand of Daiichi Sankkyo, generated total annual sales of $62.4 million in the US, a Ranbaxy statement said. Ranbaxy would have exclusive marketing rights for the drug for a period of 180 days.
Arun Sawhney, CEO and Managing Director of Ranbaxy, said “This authorised generic form of Evoxac is an excellent example of optimizing operational synergies that exists between Ranbaxy and Daiichi Sankyo, while accelerating our global business efforts. We see a continuing opportunity to leverage our combined strengths of innovation and the manufacture and marketing of affordable, high quality, generic medicines through this collaboration.”
